Approval · Notice of Compliance 278 · 2004
ZOCOR: Notice of Compliance 278
Issued March 23, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 278
- Date
- March 23, 2004
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: in patients at high risk of coronary events regardless of lipid status
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOCOR | Not yet assigned | — |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB